logo
The real Paleo diet: Neanderthals dined on rotten meat and maggots, study suggests

The real Paleo diet: Neanderthals dined on rotten meat and maggots, study suggests

CTV News3 days ago
Lead author Melanie Beasley captured this image of a "maggot mass" for a follow-up study related to the newly released paper. (Melanie Beasley via CNN Newsource)
Neanderthals had a voracious appetite for meat. They hunted big game and chowed down on woolly mammoth steak as they huddled around a fire. Or so thought many archaeologists who study the Stone Age.
Fresh meat was far from the only thing on the menu, according to a growing body of research that has revealed our archaic cousins ate a varied diet that included pulses and shellfish.
Still, a chemical signature in Neanderthal remains that suggests robust meat eating — observed at higher levels than those seen in top predators such as lions and wolves — has puzzled researchers for decades. Now, new research hints at an unexpected Stone Age food.
Maggots — the larvae of flies, which hatch in and feed on decaying animal tissue — may also have been a staple of prehistoric diets, a study published Friday in the journal Science Advances suggests.
Lead author Melanie Beasley, an assistant professor of biological anthropology at Purdue University in West Lafayette, Indiana, found that a taste for maggots could explain a distinctive chemical signature detected in the bones of prehistoric humans, including Homo sapiens and Neanderthals, a species that went extinct 40,000 years ago.
The findings back up a hypothesis that had been put forward by Beasley's coauthor John Speth, an anthropologist at the University of Michigan, who has for nearly a decade argued that putrid meat and fish would have formed a key part of prehistoric diets. His work was based on ethnographic accounts of the diets of indigenous groups, who he said found rotten meat and maggots acceptable fare.
'Not a lot of people took notice, because it was like this is an out-there idea. And there wasn't any data,' said Beasley, who heard Speth give a talk in 2017 and subsequently decided to test his hypothesis.
Understanding past diets
To understand past diets and where an animal sat in the ancient food chain, scientists study the chemical signature of different isotopes, or variants, of elements such as nitrogen or carbon, which are preserved in teeth and bones over thousands of years.
Researchers first found in the 1990s that the fossilized bones of Neanderthals unearthed in Northern Europe had particularly elevated levels of the nitrogen-15 isotope, a chemical signature that suggests their meat consumption was on par with hypercarnivores such as lions or wolves.
'Grass will have one (nitrogen) value, but then the deer that eats the grass is going to have a higher value, and then the carnivore that eats the deer is going to have an even higher value,' Beasley explained. 'So you can track nitrogen through this trophic food web system.' Neanderthal remains, she said, had even higher nitrogen values than carnivores.
This was puzzling, however, because modern-day humans, unlike wolves and lions, cannot stomach large quantities of lean meat. Overindulging in it can lead to a potentially lethal form of malnutrition in which the liver fails to break down the protein and rid the body of excess nitrogen.
Known today as protein poisoning, the condition was more common among European explorers of North America — who dubbed the illness 'rabbit poisoning' or 'mal de caribou' — given that wild game was far leaner than today's farmed meat. Archaeologists believe that Neanderthals understood the importance of fatty nutrients, and, at least in one location in what's now Germany, processed animal bones on a large scale to extract the fat.
Rotten meat might be higher in nitrogen than fresh tissue and may have been responsible for boosting nitrogen levels in Neanderthal bones, Speth's research has suggested.
Not long after hearing Speth speak, Beasley, who was previously a postdoctoral fellow at the University of Tennessee, Knoxville, where she conducted research at its Forensic Anthropology Center, decided to investigate. The research facility, sometimes described as a body farm, was established to study how the human body decomposes.
There, she analyzed nitrogen levels in the rotting tissue of donated human corpses left outdoors and the fly larvae that formed in the muscle tissue. The work, conducted over a two-year period, required a strong stomach, she said.
Beasley found that nitrogen levels increased modestly over time in the human tissue. However, she observed much higher nitrogen levels in the fly larvae, suggesting that Neanderthals and early modern humans likely consumed animal meat laced with maggots on a regular basis.
'I started getting the (nitrogen) values back, and they were just astronomically high,' Beasley recalled.
'John (Speth) and I started talking: What if it's not just the putrid meat, but it's the fact that … they're never going to be able to prevent flies from coming and landing on the meat, and so fly larva just become part of the delicacy,' she said.
The data from her work not only provides insight into the Neanderthal diet but also informs modern forensic science, with nitrogen levels in maggots that form in human corpses helping scientists pinpoint time since death, she noted.
'No brainer'
It was a 'no brainer' that Neanderthals ate maggots, said Karen Hardy, a professor of prehistoric archaeology at the University of Glasgow in Scotland.
Hardy, who wasn't involved in the study, said the authors provided a 'strong argument in favor of maggot consumption,' although such behavior is unlikely to be conclusively proven because maggot remains do not survive in the archaeological record.
'The surprise element is more to do with our Western perspective on what is edible and what is not,' she added.
Today, at least 2 billion people worldwide are estimated to consume insects as part of traditional diets, according to the United Nations Food and Agriculture Organization.
The study also noted that, according to historical accounts, many indigenous peoples such as the Inuit 'viewed thoroughly putrefied, maggot-infested animal foods as highly desirable fare, not starvation rations.' Many such groups, according to the study, 'routinely, often intentionally, allowed animal foods to decompose to the point where they were crawling with maggots, in some cases even beginning to liquify, and inevitably emitting a stench so overpowering that early European explorers, fur trappers, and missionaries were sickened by it.'
Knud Rasmussen, a polar explorer from Greenland, recorded the following culinary experience, cited in the study, in his 1931 book 'The Netsilik Eskimos: Social Life and Spiritual Culture.'
'The meat was green with age, and when we made a cut in it, it was like the bursting of a boil, so full of great white maggots was it. To my horror my companions scooped out handfuls of the crawling things and ate them with evident relish. I criticised their taste, but they … said, not illogically: 'You yourself like caribou meat, and what are these maggots but live caribou meat? They taste just the same as the meat and are refreshing to the mouth.'
The study also noted that maggots are not unknown in Western culinary traditions, noting the Sardinian cheese casu marzu is replete with the larvae of cheese skipper flies.
Beasley said that Northern latitude groups still process these foods today and consume them safely when prepared following traditional practices.
Limitations
Beasley's research on modern-day corpses was exploratory and had several limitations, she cautioned.
The work, which involved small sample sizes, focused on human muscle tissue, not the tissue or organs of animals that might have been hunted by Neanderthals. What's more, the fly larvae, which came from three different families, might have differed from those that existed in the late Pleistocene, which ended around 11,000 years ago.
The study also didn't account for the wide variety of climates and temperatures that would have had an effect on stored meat in the Stone Age. She also added that the human body tissue wasn't cooked, processed or prepared in any way.
Beasley has spoken with researchers in Alaska in the hopes of connecting with native groups that would be interested in sharing traditional food preparations. Her goal is to better understand how that might affect the nitrogen level.
The new research has 'opened a fascinating line of inquiry' into the culinary practices of Stone Age hunter-gatherers such as Neanderthals, said Wil Roebroeks, professor emeritus of paleolithic archaeology at Leiden University in the Netherlands. He wasn't involved in the research.
'It certainly gives a fresh — if that is the right word here — perspective on Neanderthal and other Late Pleistocene humans' diets,' Roebroeks added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value
Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value

National Post

time5 hours ago

  • National Post

Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value

Article content SALT LAKE CITY — Echo, the global leader in hydrogen health technology, is responding forcefully to a wave of misinformation being spread by influencers with financial agendas. False claims that the Echo Flask causes heavy metals poisoning or stops working after six months are not only wrong—they're dangerous. Article content 'Hydrogen health is growing fast—and that growth has attracted a swarm of pseudo-scientific influencers using fear, not facts, to push products that pay them more money,' said Josh Carr, CEO of Echo. 'We're done letting those lies go unchallenged.' Article content At the center of the recent smear campaign are false allegations that Echo's hydrogen water bottle stops producing hydrogen after six months and may leach harmful metals. These claims are categorically false, unsupported by any lab data, and contradicted by third-party testing and thousands of happy customers. Article content The Echo Flask is engineered with platinum-coated electrodes, a proprietary proton exchange membrane, and a self-cleaning system—guaranteeing high-concentration hydrogen performance for over 10,000 uses. Echo backs every unit with a 5-year warranty and provides published test results verifying both hydrogen output and water purity. Article content 'These accusations aren't coming from scientists or doctors. They're coming from influencers who make more money when they scare people into buying hydrogen tablets,' Carr said. 'They claim our bottle causes 'heavy metals poisoning,' but produce no lab report, no data—just fear bait.' Article content Echo acknowledges that some low-end hydrogen bottles do degrade quickly—especially those built with cheap electrodes or mass-produced knockoff parts. But the Echo Flask is in a different class: medical-grade materials, clean hydrogen output, and durable construction backed by a decade of engineering. Article content In contrast, hydrogen tablets—often promoted as a better alternative—have major safety, quality, and cost issues. Many contain unregulated magnesium, along with heavy metals like lead, and begin to degrade rapidly the moment you open the package. Article content 'These tablet pushers mislead the public with confusing numbers and manipulated science,' Carr continued. 'They talk about 'high ppm levels' as if that means something useful—but hydrogen dosage is measured in milligrams, not parts per million. A high ppm in a tiny volume can mean a low actual dose. Consumers are literally paying more for less. It's dirty, expensive water with barely any usable hydrogen.' Article content Beyond misleading metrics, tablets are a recurring cost—often over $150/month to match the hydrogen levels the Echo Flask delivers for pennies per day. They're unstable, expensive, and fundamentally misrepresented. Article content 'We've tested these tablets. We've tested our bottles. We publish our data. And we stand behind our technology. That's the difference,' said Carr. 'People deserve truth—not hype.' Article content As the hydrogen wellness category continues to grow, Echo urges consumers to look past influencer theatrics and focus on science, transparency, and value. For third-party test results, hydrogen education, and Echo's full product lineup, visit Article content Article content Article content Article content

UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025
UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025

CTV News

time5 hours ago

  • CTV News

UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025

The logo for UnitedHealth Group appears above a trading post on the floor of the New York Stock Exchange, April 17, 2025. (AP Photo/Richard Drew, file) UnitedHealth delivered disappointing second-quarter earnings and went conservative with its 2025 forecast as soaring medical costs continue to swamp insurers. The health care giant said Tuesday expenses that have jumped beyond what it expected when it set coverage prices will continue to pressure its performance. But the company expects a return to earnings growth in 2026. UnitedHealth now expects adjusted earnings of at least $16 per share in 2025 after withdrawing its previous forecast in May. It had started 2025 with expectations of making up to $30 per share. For the full year, analysts forecast earnings of $20.64 per share, according to the data firm FactSet. UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. The Eden Prairie, Minnesota, company also operates a growing Optum business that provides care and technology support. In May, the company withdrew its 2025 forecast due to higher-than-expected medical costs, and CEO Andrew Witty departed the company abruptly. He was replaced by Chairman Stephen Hemsley, who was the UnitedHealth CEO for more than a decade until 2017. That came after the company took the rare step in April of cutting its forecast. That pushed UnitedHealth shares down $130 in its worst single-day performance in over 25 years. Hemsley promised in June that UnitedHealth would establish a 'prudent' 2025 earnings outlook when it detailed second-quarter results. He also said the company had underestimated care activity and cost trends, but improvements were being made. In the second quarter, UnitedHealth reported adjusted earnings of $4.08 per share on $111.6 billion in total revenue. Analysts expected earnings of $4.48 per share on $111.5 billion in revenue, according to FactSet. The company's profit fell 19% to $3.41 billion even as revenue rose 13%. Medical costs, the company's biggest operating expense, jumped 20% to $78.6 billion in the quarter. UnitedHealth is normally the first insurer to report earnings every quarter. But this summer, it followed competitors like Elevance Health Inc. and Centene Corp. that have lowered their annual forecasts and delivered disappointing results. Several insurers say they have been hit by medical costs that are growing faster than expected. Companies have seen a rise in expensive emergency rooms visits and growing prescription drug costs, especially from expensive cancer treatments and gene therapy. They've also seen a rise in behavioral health care, which includes the treatment of mental health conditions and substance use disorders. UnitedHealth shares slid about more than 3% to $272.30 before the opening bell Tuesday. That price topped $630 last November to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. Shares are down 44% so far this year. The Dow Jones Industrial Average, of which UnitedHealth is a member, has climbed 5%. Tom Murphy, The Associated Press

Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL
Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL

Globe and Mail

time5 hours ago

  • Globe and Mail

Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL

(LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly and Company, in collaboration with Loxo Oncology Inc., is conducting a Phase 3 study titled 'A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)'. The study aims to evaluate the efficacy and safety of the experimental drug Pirtobrutinib compared to the standard treatment of Bendamustine plus Rituximab in patients who have not received prior treatment for CLL/SLL. The study tests two interventions: Pirtobrutinib, an oral medication, and a combination of Bendamustine and Rituximab, administered intravenously. Pirtobrutinib is being evaluated for its potential to offer a more effective and safer treatment option. This interventional study is randomized with a parallel assignment model. Participants are divided equally into two groups, with no masking involved. The primary purpose is treatment, allowing crossover for patients with disease progression. The study began on September 23, 2021, with an active but not recruiting status. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial for tracking the study's development and anticipated results. The outcome of this study could significantly impact Eli Lilly's and Loxo Oncology's stock performance by potentially introducing a new treatment option in the CLL/SLL market. This could influence investor sentiment positively, especially if Pirtobrutinib proves to be a superior treatment. Competitors in the oncology space will be closely monitoring these developments. The study remains active, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store